IRIS
CECCHERINI SILBERSTEIN, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 63.057
EU - Europa 6.060
AS - Asia 3.095
SA - Sud America 68
AF - Africa 57
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 21
Totale 72.384
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 63.011
SG - Singapore 1.770
IT - Italia 1.024
DE - Germania 834
IE - Irlanda 801
UA - Ucraina 793
CN - Cina 675
SE - Svezia 661
RU - Federazione Russa 477
KR - Corea 423
PL - Polonia 372
FR - Francia 365
GB - Regno Unito 287
FI - Finlandia 219
BE - Belgio 56
VN - Vietnam 46
CZ - Repubblica Ceca 45
NL - Olanda 40
CA - Canada 38
HK - Hong Kong 37
JP - Giappone 35
ES - Italia 32
BR - Brasile 22
IN - India 22
ET - Etiopia 19
PK - Pakistan 18
AU - Australia 17
EU - Europa 16
CL - Cile 15
CM - Camerun 15
CH - Svizzera 13
RO - Romania 12
TR - Turchia 11
AR - Argentina 10
CO - Colombia 10
AT - Austria 9
BD - Bangladesh 9
NZ - Nuova Zelanda 9
UZ - Uzbekistan 8
GR - Grecia 7
KG - Kirghizistan 7
PE - Perù 7
AE - Emirati Arabi Uniti 5
ZA - Sudafrica 5
A2 - ???statistics.table.value.countryCode.A2??? 4
DM - Dominica 4
IR - Iran 4
MY - Malesia 4
NG - Nigeria 4
SC - Seychelles 4
DK - Danimarca 3
EC - Ecuador 3
IL - Israele 3
MX - Messico 3
PH - Filippine 3
TW - Taiwan 3
UG - Uganda 3
AM - Armenia 2
EG - Egitto 2
GH - Ghana 2
HU - Ungheria 2
ID - Indonesia 2
KZ - Kazakistan 2
MN - Mongolia 2
A1 - Anonimo 1
AL - Albania 1
BG - Bulgaria 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
LB - Libano 1
LK - Sri Lanka 1
MA - Marocco 1
MD - Moldavia 1
NO - Norvegia 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
VA - Santa Sede (Città del Vaticano) 1
ZW - Zimbabwe 1
Totale 72.384
Salva come PNG Salva come JPEG
Città #
Woodbridge 17.842
Wilmington 17.507
Houston 14.306
Fairfield 2.223
Singapore 1.542
Chandler 1.405
Ann Arbor 1.369
Ashburn 976
Seattle 880
Cambridge 722
Dublin 691
Jacksonville 659
Medford 496
Rome 427
Santa Clara 398
Dearborn 368
Kraków 359
Beijing 309
New York 244
Lawrence 232
San Diego 156
Menlo Park 125
Milan 122
Mülheim 103
Moscow 101
Zhengzhou 68
Munich 65
London 62
Creede 61
Brussels 53
Helsinki 53
Boardman 49
Palo Alto 44
Redwood City 44
Phoenix 42
Falls Church 41
San Francisco 38
Cedarhurst 35
Mountain View 33
Nanjing 32
Colorado Springs 30
University Park 30
Brno 29
Dong Ket 29
Norwalk 29
Hong Kong 26
Kunming 26
Nuremberg 26
Guangzhou 24
Los Angeles 24
Verona 24
Shanghai 23
Engelhard 22
Hefei 21
Washington 21
Hangzhou 20
Saint Petersburg 20
Council Bluffs 19
Toronto 18
La Veta 17
Seoul 17
Olomouc 16
Bari 15
San Mateo 15
Amsterdam 14
Madrid 14
Naples 14
Wuhan 14
Chicago 13
Jinan 13
Manitou Springs 12
Padova 12
Tokyo 12
Hanoi 11
Nanchang 11
San Jose 11
St. George 11
Genoa 10
Kilburn 10
Nürnberg 10
Indiana 9
Lappeenranta 9
Shenyang 9
Addis Ababa 8
Auckland 8
São Paulo 8
Tappahannock 8
Florence 7
Hebei 7
Hounslow 7
Lahore 7
Nepi 7
Bogotá 6
Detroit 6
Fuzhou 6
Genzano di Roma 6
Islington 6
Montréal 6
Stockholm 6
Acton 5
Totale 65.156
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 512
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 496
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 472
Virologic correlates of adherence to antiretroviral medications and therapeutic failure 461
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 460
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 448
Novel drug resistance mutations in HIV: Recognition and clinical relevance 446
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 446
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 446
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 446
Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes 442
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 440
Understanding HIV compartments and reservoirs 437
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 436
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 435
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 430
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 429
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 429
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 429
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients 427
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 423
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 423
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 423
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 423
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 421
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 420
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 419
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors 418
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 416
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin 415
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 414
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 412
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 408
Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso 406
Gene transfer in astrocytes: comparison between different delivering methods and expression of the HIV-1 protein Nef 406
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 405
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 404
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 403
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 402
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy 401
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 400
HIV-Infected Late Presenter Patients 400
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 400
A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy 400
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 398
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 398
Molecular diversity of HIV in Albania 395
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 394
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 394
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype 394
The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors 392
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 392
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 392
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 391
Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients 390
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 390
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure 387
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 387
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 386
Incomplete APOBEC3G/F neutralization by HIV-1 Vif mutants facilitates the genetic evolution from CCR5 to CXCR4 usage 386
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 385
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 384
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 384
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort 384
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation 382
Molecular dynamics and free energy studies on the wild-type and mutated hiv-1 protease complexed with four approved drugs: Mechanism of binding and drug resistance 381
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 380
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes 380
The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs 379
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 379
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study 379
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 378
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 377
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 377
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria 376
Dynamics of NRTI resistance mutations during therapy interruption 375
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 374
Short communication: Population-based surveillance of HIV-1 drug resistance in cameroonian adults initiating antiretroviral therapy according to the world health organization guidelines 374
Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation 374
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 372
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 372
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 372
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 372
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 370
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors 369
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 369
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics 369
The use of human immunodeficiency virus resistance tests in clinical practice 369
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors 368
The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A 368
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations 368
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data 368
Temporal change in the use of genotypic resistance testing over the years 1999--2003 367
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 367
Identification of a novel Rev-interacting cellular protein 366
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 366
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 366
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 366
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 365
From current status to optimization of HCV treatment: Recommendations from an expert panel 364
Totale 40.030
Salva come PNG Salva come JPEG
Categoria #
all - tutte 162.646
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 162.646
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012.780 0 0 0 0 1.652 2.084 1.763 1.614 1.615 1.655 1.145 1.252
2020/202111.007 1.246 1.205 1.203 1.458 1.021 1.196 1.571 1.007 241 290 384 185
2021/20223.041 131 226 199 152 124 231 185 132 577 245 150 689
2022/20233.882 423 301 196 457 358 800 273 371 322 44 241 96
2023/20241.544 227 47 94 59 125 269 77 62 57 209 36 282
2024/20253.644 282 1.724 944 486 208 0 0 0 0 0 0 0
Totale 73.382